The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients

Purposes Most molecular-based published studies on breast cancer do not adequately represent the unique and diverse genetic admixture of the Latin American population. Searching for similarities and differences in molecular pathways associated with these tumors and evaluating its impact on prognosis may help to select better therapeutic approaches. Patients and Methods We collected clinical, pathological, and transcriptomic data of a multi-country Latin American cohort of 1,071 stage II-III breast cancer patients of the Molecular Profile of Breast Cancer Study (MPBCS) cohort. The 5-year prognostic ability of intrinsic (transcriptomic-based) PAM50 and immunohistochemical classifications, both at the cancer-specific (OSC) and disease-free survival (DFS) stages, was compared. Pathway analyses (GSEA, GSVA and MetaCore) were performed to explore differences among intrinsic subtypes. Results PAM50 classification of the MPBCS cohort defined 42·6% of tumors as LumA, 21·3% as LumB, 13·3% as HER2E and 16·6% as Basal. Both OSC and DFS for LumA tumors were significantly better than for other subtypes, while Basal tumors had the worst prognosis. While the prognostic power of traditional subtypes calculated with hormone receptors (HR), HER2 and Ki67 determinations showed an acceptable performance, PAM50-derived risk of recurrence best discriminated low, intermediate and high-risk groups. Transcriptomic pathway analysis showed high proliferation (i.e. cell cycle control and DNA damage repair) associated with LumB, HER2E and Basal tumors, and a strong dependency on the estrogen pathway for LumA. Terms related to both innate and adaptive immune responses were seen predominantly upregulated in Basal tumors, and, to a lesser extent, in HER2E, with respect to LumA and B tumors. Conclusions This is the first study that assesses molecular features at the transcriptomic level in a multicountry Latin American breast cancer patient cohort. Hormone-related and proliferation pathways that predominate in PAM50 and other breast cancer molecular classifications are also the main tumor-driving mechanisms in this cohort and have prognostic power. The immune-related features seen in the most aggressive subtypes may pave the way for therapeutic approaches not yet disseminated in Latin America. Clinical Trial Registration ClinicalTrials.gov (Identifier: NCT02326857).

[1]  F. Markowetz,et al.  Multi-omic machine learning predictor of breast cancer therapy response , 2021, Nature.

[2]  Steven H. Lin,et al.  Profiling of immune features to predict immunotherapy efficacy , 2021, Innovation.

[3]  E. Perez,et al.  The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group , 2021, NPJ breast cancer.

[4]  N. Radosevic-Robin,et al.  Refining patient selection for breast cancer immunotherapy: beyond PD-L1 , 2021, ESMO open.

[5]  Stephen R. Williams,et al.  A single-cell and spatially resolved atlas of human breast cancers , 2021, Nature Genetics.

[6]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Krishna R. Kalari,et al.  FOXA1 overexpression suppresses interferon signaling and immune response in cancer. , 2021, The Journal of clinical investigation.

[8]  A. Musolino,et al.  Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression , 2021, Molecular Diagnosis & Therapy.

[9]  C. Denkert,et al.  Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. , 2021, JAMA oncology.

[10]  M. Ellis,et al.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.

[11]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[12]  Melissa B. Davis,et al.  Cancer health disparities in racial/ethnic minorities in the United States , 2020, British Journal of Cancer.

[13]  Jeffrey S. Damrauer,et al.  Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer , 2020, Cancer Cell.

[14]  Nikos Koundouros,et al.  Reprogramming of fatty acid metabolism in cancer , 2019, British Journal of Cancer.

[15]  B. Boone,et al.  Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment , 2019, Breast Cancer Research.

[16]  M. Shaul,et al.  Tumour-associated neutrophils in patients with cancer , 2019, Nature Reviews Clinical Oncology.

[17]  Joseph O Deasy,et al.  Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes , 2019, npj Breast Cancer.

[18]  Maria Anna Rapsomaniki,et al.  A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer , 2019, Cell.

[19]  Benjamin Haibe-Kains,et al.  Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers , 2019, The Journal of clinical investigation.

[20]  L. Pusztai,et al.  Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women , 2019, Breast Cancer Research and Treatment.

[21]  J. Dutil,et al.  Genetic Epidemiology of Breast Cancer in Latin America , 2019, Genes.

[22]  K. Polyak,et al.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. , 2019, Cancer discovery.

[23]  F. Gaete,et al.  Triple-negative breast cancer: the reality in Chile and in Latin America , 2019, Ecancermedicalscience.

[24]  S. Neuhausen,et al.  Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity , 2019, Oncotarget.

[25]  Xin Hu,et al.  Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics , 2018, Breast Cancer Research and Treatment.

[26]  J. Lee,et al.  Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort , 2018, Breast Cancer Research and Treatment.

[27]  J. Sáez-Rodríguez,et al.  Benchmark and integration of resources for the estimation of human transcription factor activities , 2018, bioRxiv.

[28]  C. Perou,et al.  Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. , 2018, Cancer treatment reviews.

[29]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[30]  N. Howlader,et al.  Differences in Breast Cancer Survival by Molecular Subtypes in the United States , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[31]  J. Reis-Filho,et al.  Triple-negative breast cancers — a panoply of cancer types , 2018, Nature Reviews Clinical Oncology.

[32]  C. Sotiriou,et al.  Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  L. Fejerman,et al.  Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[34]  C. Perou,et al.  Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts , 2017, Clinical Cancer Research.

[35]  M. Monaco.  Fatty acid metabolism in breast cancer subtypes , 2017, Oncotarget.

[36]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[37]  L. Miele,et al.  High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. , 2016, Carcinogenesis.

[38]  E. Perez-stable,et al.  Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry , 2016, Current Epidemiology Reports.

[39]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[40]  Xin Hu,et al.  Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[41]  O. Podhajcer,et al.  Translational cancer research comes of age in Latin America , 2015, Science Translational Medicine.

[42]  Jacques Ferlay,et al.  International Variation in Female Breast Cancer Incidence and Mortality Rates , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[43]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[44]  John M S Bartlett,et al.  An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.

[45]  C. Caldas,et al.  PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[47]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[48]  M. Weller,et al.  Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil , 2014, BMC Women's Health.

[49]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[50]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[51]  Mark T. W. Ebbert,et al.  Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[52]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[53]  L. Natarajan,et al.  Reproductive Factors, Heterogeneity, and Breast Tumor Subtypes in Women of Mexican Descent , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[54]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Richard Sullivan,et al.  Planning cancer control in Latin America and the Caribbean. , 2013, The Lancet. Oncology.

[56]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[57]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[58]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[59]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[60]  Xi Chen,et al.  TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer , 2012, Cancer informatics.

[61]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[62]  Yufeng Liu,et al.  Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures , 2011, BMC Medical Genomics.

[63]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[64]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[65]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[66]  M. Abba,et al.  Breast Cancer Biomarker Discovery in the Functional Genomic Age: A Systematic Review of 42 Gene Expression Signatures , 2010, Biomarker insights.

[67]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[69]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[70]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[71]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[72]  Jacob Cohen,et al.  Set Correlation and Contingency Tables , 1988 .

[73]  I. Endo,et al.  Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. , 2021, American journal of cancer research.

[74]  Nuno A. Fonseca,et al.  Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer. , 2018, Cancer research.

[75]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.